Data Sheet | May 29, 2026
DynamiQ™ Normal Human Tissue Proteomics Atlas
Get the Resource
DynamiQ Databases - Request
Request access to our DynamiQ atlases.
"*" indicates required fields
Most modern oncology therapeutics, from ADCs to T-cell engagers, radioligand therapies, and targeted biologics, are designed to engage specific protein targets on tumor cells. However, these targets are rarely exclusive to tumors. When a drug engages its intended target in normal tissues such as heart, lung, liver, or kidney, the consequence is on-target, off-tissue toxicity – one of the leading causes of dose limitation, clinical holds, and program failure.
The DynamiQ Normal Human Tissue Proteomics Atlas provides a reference map of normal human tissue biology through multi-dimensional proteomic characterization across the primary organs associated with dose-limiting toxicities.
Combining direct measures of protein expression, signaling activity, cell surface accessibility, immune biology, and resistance pathways across 15+ normal human tissues, the DynamiQ atlas enables drug developers to identify novel therapeutic targets and evaluate on-target, off-tissue safety liabilities before reaching the clinic.
Multi-Dimensional Proteomic Profiling
Each tissue in the DynamiQ Normal Human Tissue Proteomics Atlas has been profiled across multiple Sapient proteomics workflows. The atlas does not simply catalog which proteins are present – it reveals how proteins are regulated, activated, and organized across normal human biology, capturing:
- Global expression across 12,000+ protein groups
- Cell surface protein expression
- Phosphorylation-driven signaling activity
- Immune cell states and pathway activity
- Resistance-associated protein networks
The atlas spans the primary organs associated with dose-limiting toxicities across modern therapeutic modalities. It delivers deep proteomic characterization across tissues such as liver, lung, heart, kidney, gastrointestinal tract, and immune compartments, creating a consistent reference framework for normal human biology.
| Tissues Characterized |
|---|
| Liver |
| Lung |
| Heart |
| Large Intestine |
| Pancreas |
| Skeletal Muscle |
| Skin |
| Kidney |
| PBMC |
| Vascular Tissue |
| Small Instestine |
| Stomach |
| Exocrine Gland |
| Uterine Tube |
| Serous Membrane |
Why Normal Human Tissue Proteomics Is Critical
Most development programs still lack reliable, protein-level data on target expression in normal human tissues and instead rely on indirect proxies such as RNA expression databases or single-cell RNA sequencing data. The challenge is that mRNA does not reliably predict protein abundance, cell surface accessibility, post-translational states, or pathway activation.
As a result, target selection is based on incomplete expression data and on-target, off-tissue toxicity is often discovered late – in Phase I or beyond. These methods can also miss novel targets with favorable therapeutic index profiles.
The DynamiQ Normal Human Tissue Proteomics Atlas shifts evaluation of normal tissue biology from inference to direct measurement. Instead of approximating protein behavior through RNA or antibody-based assays, it provides quantitative proteomic data across multiple biological dimensions.
Download the white sheet to explore how the DynamiQ atlas delivers a comprehensive reference map of normal human tissue biology – and how it can be applied in your programs to enable more informed safety and target selection decisions.
What development questions can I answer with the DynamiQ Normal Human Tissue Proteomics Atlas?
By comparing tumor datasets against normal tissue proteomics baselines, teams can identify proteins that are highly enriched in tumors but minimally expressed in healthy tissues. This supports selection of targets with more favorable therapeutic index profiles.
In addition, the atlas provides baseline biological context that is often missing from traditional datasets. Understanding which signaling pathways are active, which immune checkpoints are present, and which resistance programs are engaged in normal tissues helps anticipate how therapies will behave in real-world physiological environments.
This reference map is particularly valuable in programs where teams are asking:
| Development Question | Depth and Insight |
|---|---|
| Is my target expressed in normal tissues? | Quantitative protein-level expression across 15+ tissues |
| Which organs are at risk for on-target toxicity? | Tissue-specific expression, surface availability, and pathway activity |
| What is the therapeutic index of my target? | Direct tumor vs. normal tissue protein expression comparison |
| Are there targets with cleaner safety profiles? | Systematic identification of tumor-selective proteins |
| Is the target on the cell surface in normal tissues? | SurfaceSeek™ surface proteomics across all profiled tissues | What signaling is active in at-risk tissues? | SignalingSeek™ phosphoproteomics baseline in normal tissues | What is the immune biology of at-risk organs? | ImmuneSeek™ immune cell and checkpoint profiling by tissue |
Normal human tissue proteomics plays a central role in evaluating both safety and efficacy early in development. By directly measuring protein expression across tissues, the atlas enables teams to determine where a target is expressed outside the tumor and which organs may be at risk for toxicity.
Access the DynamiQ Normal Human Tissue Proteomics Atlas – Get Started Today
The atlas can be applied across early discovery, target selection, IND-enabling programs, and clinical development. It is available through flexible data licensing and proteomics services models, including data access for specific targets, integration with internal workflows, and custom proteomics studies using client-provided samples.
Use the form to request a meeting or email discover@sapient.bio to set up a time to talk about your study needs.
Get the Resource
DynamiQ Databases - Request
Request access to our DynamiQ atlases.
"*" indicates required fields